AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
● Severe acute respiratory syndrome coronavirus 2–related coronavirus GX/P2V/2017 infects mice with moderate pathogenicity.
● ZF2001 vaccination protects mice against GX/P2V/2017 infection.
● Sera from people vaccinated with ZF2001 cross-react and cross-neutralize GX/P2V/2017.
Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related coronaviruses have been discovered, constituting potential threats to human health. However, it remains unclear whether the currently available vaccines are effective against these coronaviruses. Here, we constructed a wild-type mouse model to evaluate pathogenicity of the SARS-CoV-2-related pangolin coronavirus GX/P2V/2017 and neutralization efficacy of the approved tandem-repeat SARS-CoV-2 spike receptor-binding domain (RBD) vaccine ZF2001. We found that ZF2001-induced cross-reactive and cross-neutralizing antibodies against GX/P2V/2017, and the vaccination alleviated the pathological lung damage caused by GX/P2V/2017 in mice. These results indicate that RBD may work as a promising candidate for pan-coronavirus vaccine development.
Tyrrell DA, Bynoe ML. Cultivation of a novel type of common-cold virus in organ cultures. Br Med J 1965;1:1467-70.
Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013;500:227-31.
Chiu SS, Chan KH, Chu KW, Kwan SW, Guan Y, Poon LL, et al. Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin Infect Dis 2005;40:1721-9.
Jean A, Quach C, Yung A, Semret M. Severity and outcome associated with human coronavirus OC43 infections among children. Pediatr Infect Dis J 2013;32:325-9.
Jevsnik M, Ursic T, Zigon N, Lusa L, Krivec U, Petrovec M. Coronavirus infections in hospitalized pediatric patients with acute respiratory tract disease. Bmc Infect Dis 2012;12:365.
Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76.
Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-66.
Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, Huang Y, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005;79:884-95.
Fouchier RA, Hartwig NG, Bestebroer TM, Niemeyer B, de Jong JC, Simon JH, et al. A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci U S A 2004;101:6212-6.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.
Delaune D, Hul V, Karlsson EA, Hassanin A, Ou TP, Baidaliuk A, et al. A novel SARS-CoV-2 related coronavirus in bats from Cambodia. Nat Commun 2021;12:6563.
Lam TT, Jia N, Zhang YW, Shum MH, Jiang JF, Zhu HC, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 2020;583:282-5.
Niu S, Wang J, Bai B, Wu L, Zheng A, Chen Q, et al. Molecular basis of cross-species ACE2 interactions with SARS-CoV-2-like viruses of pangolin origin. Embo J 2021;40:e107786.
Guo Z, Zhang C, Zhang C, Cui H, Chen Z, Jiang X, et al. SARS-CoV-2-related pangolin coronavirus exhibits similar infection characteristics to SARS-CoV-2 and direct contact transmissibility in hamsters. Iscience 2022;25:104350.
Dai L, Gao L, Tao L, Hadinegoro SR, Erkin M, Ying Z, et al. Efficacy and safety of the RBD-dimer-based COVID-19 vaccine ZF2001 in adults. N Engl J Med 2022;386:2097-111.
Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis 2021;21:1107-19.
An Y, Li S, Jin X, Han JB, Xu K, Xu S, et al. A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates. Emerg Microbes Infect 2022;11:1058-71.
Jia Y, Niu S, Hu Y, Chai Y, Zheng A, Su C, et al. Cross-reaction of current available SARS-CoV-2 mabs against the pangolin-origin coronavirus GX/P2V/2017. Cell Rep 2022;41:111831.
Xu ZP, Kang XR, Han P, Du P, Li LJ, Zheng AQ, et al. Binding and structural basis of equine ACE2 to RBDs from SARS-CoV, SARS-CoV-2 and related coronaviruses. Nat Commun 2022;13:3547.
Gu H, Chen Q, Yang G, He L, Fan H, Deng YQ, et al. Adaptation of SARS-CoV-2 in balb/c mice for testing vaccine efficacy. Science 2020;369:1603-7.
Leist SR,, Schafer A, Tse LV, Okuda K, Hou YJ, et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 2020;183:1070-1085 e12.
Dinnon 3rd KH, Leist SR, Schafer A, Edwards CE, Martinez DR, Montgomery SA, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 2020;586:560-6.
Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. Febs J 2018;285:2944-71.
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-4.
Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 2020;584:120-4.
Burton DR, Walker LM. Rational vaccine design in the time of COVID-19. Cell Host Microbe 2020;27:695-8.
Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 2020;368:1274-8.
Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 2020;182:722-733 e11.
Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, et al. A vaccine targeting the RBD of the s protein of SARS-CoV-2 induces protective immunity. Nature 2020;586:572-7.
Tai W, Zhang X, Drelich A, Shi J, Hsu JC, Luchsinger L, et al. A novel receptor-binding domain (RBD)-based mrna vaccine against SARS-CoV-2. Cell Res 2020;30:932-5.
Huang Q, Ji K, Tian S, Wang F, Huang B, Tong Z, et al. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nat Commun 2021;12:776.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33.
Liu K, Pan X, Li L, Yu F, Zheng A, Du P, et al. Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species. Cell 2021;184:3438-3451 e10.
Zhou P, Fan H, Lan T, Yang XL, Shi WF, Zhang W, et al. Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin. Nature 2018;556:255-8.
Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1977-85.
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20.
Wu L, Chen Q, Liu K, Wang J, Han P, Zhang Y, et al. Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. Cell Discov 2020;6:68.
van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, Wolthers KC, et al. Identification of a new human coronavirus. Nat Med 2004;10:368-73.
Wang N, Luo C, Liu H, Yang X, Hu B, Zhang W, et al. Characterization of a new member of alphacoronavirus with unique genomic features in Rhinolophus bats. Viruses 2019;11:379.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
